c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays
Open Access
- 23 January 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 96 (2), 329-335
- https://doi.org/10.1038/sj.bjc.6603569
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: Retrospective study in a series of 745 patientsInternational Journal of Cancer, 2005
- Prognostic Significance of Co-expression of RON and MET Receptors in Node-Negative Breast Cancer PatientsClinical Cancer Research, 2005
- Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open QuestionsJournal of Clinical Oncology, 2005
- Tumor Neoangiogenesis by CD31 and CD105 Expression Evaluation in Breast Carcinoma Tissue MicroarraysClinical Cancer Research, 2004
- Met, metastasis, motility and moreNature Reviews Molecular Cell Biology, 2003
- Tissue microarray‐based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptorsCancer, 2003
- Hypoxia promotes invasive growth by transcriptional activation of the met protooncogeneCancer Cell, 2003
- Scatter-factor and semaphorin receptors: cell signalling for invasive growthNature Reviews Cancer, 2002
- c‐met tyrosine kinase receptor expression is associated with abnormal β‐catenin expression and favourable prognostic factors in invasive breast carcinomaHistopathology, 2000
- Quantitative Immuno cytochemical Assays of P-glycoprotein in Breast Carcinomas: Correlation to Messenger RNA Expression and to Immunohistochemical Prognostic IndicatorsJNCI Journal of the National Cancer Institute, 1994